Navigation

    Forum

    • Register
    • Login
    • Search
    • Categories
    • Recent
    • Popular
    • Users
    • Groups

    consensus guidelines

    Claims & Support/References for Claims
    2
    2
    96
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • F
      Fernand last edited by

      The NCCN guidelines for a cancerX recommended products of class A for Stages III-IV in line with the recommended label. However, they have just been updated to include same products for Stages II-IV, recognizing that "supporting data are limited for stage II". The rationale for this revision / inclusion is the following: "Cases of stage II disease at initial diagnosis are rare, especially among patients who have undergone complete surgical staging, so there are little data and low probability of future trials that will address the question of whether it is appropriate to use class A as maintenance after completing primary therapy for stage II disease." Our question to the PAAB is whether we can use these new recommendations as part of the promotional materials with a disclaimer that our indication is for "advanced stages of cancerX".

      Jennifer Carroll 1 Reply Last reply Reply Quote 0
      • Jennifer Carroll
        Jennifer Carroll @Fernand last edited by

        Hey @fernand

        Generally, promotion of place in therapy claims from consensus guidelines should be within the limitations of the indication and terms of market authorization. As it sounds like this is an off-label recommendation, it would not be acceptable. The Marketing Benefits Claims document also includes this definition.

        1 Reply Last reply Reply Quote 0
        • First post
          Last post